Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Coya Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, joins Coya's Board of Directors"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results"
07/14/2023 8-K Quarterly results
07/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, between the Company and Dr. Fred Grossman"
06/29/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Coya Therapeutics' CEO Dr. Howard Berman's Letter to Stockholders"
05/23/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/19/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/19/2023 ARS Form ARS - Annual Report to Security Holders:
05/19/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/16/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Coya Therapeutics' COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer's Disease",
"Poster Presentation of Coya Therapeutics, Inc"
05/12/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
05/11/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results"
05/08/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/29/2023 10-K Annual Report for the period ended December 31, 2022
03/29/2023 8-K Quarterly results
03/22/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
03/21/2023 8-K Investor presentation
Docs: "Presentation of Coya Therapeutics, Inc"
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/01/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 SC 13G Berman Howard reports a 14.2% stake in COYA THERAPEUTICS, INC.
01/25/2023 8-K Other Events  Interactive Data
01/05/2023 SC 13G HIRSCHMAN ORIN reports a 7.2% stake in Coya Therapeutics, Inc.
12/30/2022 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
12/29/2022 CERT Form CERT - Certification by an exchange approving securities for listing:
12/29/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/12/2022 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
12/06/2022 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
12/05/2022 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy